Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) unit Chengdu Shengdi Pharmaceutical received approval from China's National Medical Products Administration to market its Oteseconazole capsules, according to a Shanghai bourse filing on Friday.
The drug is indicated for the treatment of severe vulvovaginal candidiasis, or yeast infection.